Skip to content

Evaluation of the Effect of an Injectable Hydrogel Carrier Containing Stem Cells on Diabetic Foot Ulcer Healing

Evaluation of the Safety and Efficacy of Transplanting an Injectable Hydrogel Carrier Laden with Mesenchymal Stem Cells for the Treatment of Patients with Diabetic Foot Ulcers: Phase 1/2 Clinical Trial (Semi-industrial Production of an Injectable MSC-Loaded Hydrogel Carrier for Chronic Wound Therapy)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250302064900N1
Enrollment
30
Registered
2025-05-29
Start date
2025-06-22
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with diabetic ulcers. Type 2 diabetes mellitus with foot ulcer

Interventions

Intervention 1: Intervention group: Recipients of two million mesenchymal stem cells in a hydrogel carrier. Intervention 2: Control group: Recipients of standard treatment.

Sponsors

Iranian academic center for education culture and research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Individuals with type 1 or type 2 diabetes who have had non-healing wounds for at least four weeks Diabetic ulcer grade 1–2 on the Wagner scale; ankle-brachial index (ABI) = 0.7; HbA1c < 12 %; wound size 2–20 cm² No use of medications that may interfere with wound healing, such as corticosteroids, immunosuppressive agents, and cytotoxic drugs

Exclusion criteria

Exclusion criteria: Use of corticosteroids, immunosuppressive agents, and cytotoxic drugs Pregnancy and breast feeding Presence of renal failure (serum creatinine > 3 mg/dL); heart failure; uncontrolled systemic infection; neuropathic disorders other than diabetic neuropathy; peripheral vascular disease; and psychiatric illness or disability Age over 80 years

Design outcomes

Primary

MeasureTime frame
Wound surface size. Timepoint: On days 3, 7, and 14, and then monthly for up to one year. Method of measurement: Measuring tool.;Wound healing rate. Timepoint: On days 3, 7, and 14, and then monthly for up to one year. Method of measurement: macroscopic evaluation.;Severity of wound pain. Timepoint: On days 3, 7, and 14, and then monthly for up to one year. Method of measurement: Pain score on a numeric rating scale.

Secondary

MeasureTime frame
Survival Risk Percentage. Timepoint: day 365. Method of measurement: Plotting the survival curve.;Risk of Amputation. Timepoint: 12 months after intervention. Method of measurement: Clinical Documentation.;Wound-Related Quality of Life Index. Timepoint: 3 months after intervention. Method of measurement: Wound-QoL.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHalimeh Hassanzadeh

Iranian academic center for education culture and research

malihehhassanzadeh748@gmail.com+98 51 3199 7453

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026